HGN - Submission of IND Application to US FDA - Dr Roger Aston, CEO
Wed, 14 May 2008 5:30pm
HALCYGEN PHARMACEUTICALS LIMITED (HGN)
Loading presentation... If nothing happens, you may need to install Flash and/or enable javascript in your browser.
Simone Parkes
HalcyGen Completes Recruitment of its US-conducted Phase II Study for SUBA®-Itraconazole: Simone Parkes, Business Development
Thu, 15 Apr 2010 2:00pm
Final Patient Recruited (175 patients) in Phase II Safety-Efficacy Study
Icon_lastIcon_nextIcon_previousIcon_first